These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33587969)

  • 1. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
    Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
    Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.
    Zhang S; Chen J; Jiang H; Ma H; Yang B
    Eur J Clin Pharmacol; 2012 May; 68(5):561-9. PubMed ID: 22231637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis.
    Su Y; Cui J; Xu D; Wang M; Xu T; Tian H; Han F
    Crit Rev Oncol Hematol; 2018 Apr; 124():11-20. PubMed ID: 29548481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Tian Y; Lin J; Tian Y; Zhang G; Zeng X; Zheng R; Zhang W; Yuan Y
    Int J Cancer; 2018 Jun; 142(11):2198-2206. PubMed ID: 29143328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta-analysis.
    Kiss F; Pohóczky K; Görbe A; Dembrovszky F; Kiss S; Hegyi P; Szakó L; Tóth L; Ezer ÉS; Szalai E; Helyes Z
    Oral Dis; 2023 Jul; 29(5):1905-1919. PubMed ID: 35485982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
    Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
    Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
    Song Q; Li X; Li B
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-EGFR monoclonal antibodies in recurrent and/or metastatic head and neck squamous cell carcinoma: a meta-analysis].
    Song Q; Li X; Li B; Di B; Xiao S
    Zhonghua Yi Xue Za Zhi; 2015 Jun; 95(22):1779-83. PubMed ID: 26704167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis.
    Keren S; Shoude Z; Lu Z; Beibei Y
    Tumour Biol; 2014 Mar; 35(3):2285-95. PubMed ID: 24234257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
    Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
    Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: a Meta-analysis].
    Song Q; Li X; Li B; Di B; Xiao S
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 May; 29(9):815-21. PubMed ID: 26281058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
    Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma.
    Xin Y; Yan Q; Yang C; Jiang F; Guo W; Huang Q; Jiang G; Zhang L
    Medicine (Baltimore); 2018 Dec; 97(51):e13717. PubMed ID: 30572506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
    Lau A; Yang WF; Li KY; Su YX
    Crit Rev Oncol Hematol; 2020 Sep; 153():102984. PubMed ID: 32569853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.